ID: ALA48981

Max Phase: Preclinical

Molecular Formula: C32H52N8O7

Molecular Weight: 660.82

Molecule Type: Protein

Associated Items:

Representations

Canonical SMILES:  CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(=O)O

Standard InChI:  InChI=1S/C32H52N8O7/c1-5-19(4)26(29(44)38-24(31(46)47)16-18(2)3)39-27(42)23(17-20-10-12-21(41)13-11-20)37-28(43)25-9-7-15-40(25)30(45)22(33)8-6-14-36-32(34)35/h10-13,18-19,22-26,41H,5-9,14-17,33H2,1-4H3,(H,37,43)(H,38,44)(H,39,42)(H,46,47)(H4,34,35,36)/t19-,22-,23-,24-,25-,26-/m0/s1

Standard InChI Key:  ORFISQWLBSTJAE-KTHKBMNISA-N

Associated Targets(Human)

NTSR1 Tchem Neurotensin receptor 1 (1525 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NTSR2 Tchem Neurotensin receptor (16 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Mus musculus (284745 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Rattus norvegicus (775804 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: ProteinTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 660.82Molecular Weight (Monoisotopic): 660.3959AlogP: -0.06#Rotatable Bonds: 18
Polar Surface Area: 255.56Molecular Species: ZWITTERIONHBA: 8HBD: 8
#RO5 Violations: 2HBA (Lipinski): 15HBD (Lipinski): 11#RO5 Violations (Lipinski): 3
CX Acidic pKa: 4.11CX Basic pKa: 11.21CX LogP: -1.27CX LogD: -1.64
Aromatic Rings: 1Heavy Atoms: 47QED Weighted: 0.06Np Likeness Score: 0.32

References

1. Cain GA, Christos TE, Johnson AL, Pottorf RS, Tam S, Schmidt WK.  (1993)  Identification of simpler analogs of neurotensin(913) which retain antinociceptive activity,  (8): [10.1016/S0960-894X(00)80059-1]
2. Lundquist JT, Dix TA..  (1999)  Preparation and receptor binding affinities of cyclic C-terminal neurotensin (8-13) and (9-13) analogues.,  (17): [PMID:10498212] [10.1016/s0960-894x(99)00420-5]
3. St-Pierre S, Lalonde JM, Gendreau M, Quirion R, Regoli D, Rioux F..  (1981)  Synthesis of peptides by the solid-phase method. 6. Neurotensin, fragments, and analogues.,  24  (4): [PMID:7265123] [10.1021/jm00136a004]
4. Lundquist JT, Büllesbach EE, Dix TA..  (2000)  Synthesis of neurotensin(9-13) analogues exhibiting enhanced human neurotensin receptor binding affinities.,  10  (5): [PMID:10743946] [10.1016/s0960-894x(00)00018-4]
5. Lundquist JT, Dix TA..  (1999)  Synthesis and human neurotensin receptor binding activities of neurotensin(8-13) analogues containing position 8 alpha-azido-N-alkylated derivatives of ornithine, lysine, and homolysine.,  42  (23): [PMID:10579853] [10.1021/jm9903444]
6. Rivier JE, Lazarus LH, Perrin MH, Brown MR..  (1977)  Neurotensin analogues. Structure--activity relationships.,  20  (11): [PMID:915901] [10.1021/jm00221a011]

Source